Cardiovascular vs Hematology — Deal Terms Comparison
Market Analysis
Cardiovascular and Hematology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 cardiovascular deals carry a median total deal value of $3.0B with $606M upfront, compared to $3.0B total value and $604M upfront for hematology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do cardiovascular and hematology deal terms compare?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating